Literature DB >> 23706257

Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era.

Allison S Glass1, Janet E Cowan, Mahesh J Fuldeore, Matthew R Cooperberg, Peter R Carroll, Stacey A Kenfield, Kirsten L Greene.   

Abstract

OBJECTIVE: To describe how demographic and diagnostic characteristics of men with prostate cancer in the United States have changed since 1999, using data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry.
METHODS: The medical records of patients enrolled in CaPSURE between 1999 and 2011 were evaluated. Baseline demographics, disease features, and imaging use were assessed. Mantel-Haenszel chi-square was used to test for trends across diagnostic years.
RESULTS: Between 1999 and 2011, a total of 9572 patients were diagnosed with prostate cancer and enrolled in CaPSURE at community (36), academic (3), and Veteran's Affairs (4) hospitals. Over the study period, mean age at diagnosis decreased, P <.01. In 2008-2011, a significant increase in diagnostic Gleason 7 or higher was observed relative to 1999-2001 (50% vs 36%, P <.01), congruent with recent guideline modifications of the Gleason classification system. An increase in the mean number of diagnostic biopsy cores (13.3 vs 8.3, P <.01) was also observed. A significant decrease in use of any imaging modality was seen (19% vs 45%, P <.01). Average pretreatment urinary and bowel function scores did not change, although there were significant increases in sexual function observed overall (P <.01).
CONCLUSION: In the United States, several trends in the demographics and disease profile of men with newly diagnosed prostate cancer were observed over the past 12 years. Decreased imaging use and increased number of cores taken during diagnostic biopsy are in line with national urologic guidelines on prostate cancer diagnosis and management.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23706257     DOI: 10.1016/j.urology.2013.01.072

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

1.  Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.

Authors:  X Garcia-Albeniz; J M Chan; A Paciorek; R W Logan; S A Kenfield; M R Cooperberg; P R Carroll; M A Hernán
Journal:  Eur J Cancer       Date:  2015-03-17       Impact factor: 9.162

2.  A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).

Authors:  Marco Randazzo; Alexander Müller; Sigrid Carlsson; Daniel Eberli; Andreas Huber; Rainer Grobholz; Lukas Manka; Ashkan Mortezavi; Tullio Sulser; Franz Recker; Maciej Kwiatkowski
Journal:  BJU Int       Date:  2015-10-06       Impact factor: 5.588

3.  Increasing use of observation among men at low risk for prostate cancer mortality.

Authors:  Chad R Ritch; Amy J Graves; Kirk A Keegan; Shenghua Ni; Jeffrey C Bassett; Sam S Chang; Matthew J Resnick; David F Penson; Daniel A Barocas
Journal:  J Urol       Date:  2014-09-06       Impact factor: 7.450

4.  Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

Authors:  Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda
Journal:  J Urol       Date:  2015-01-28       Impact factor: 7.450

5.  A urine-based methylation signature for risk stratification within low-risk prostate cancer.

Authors:  T A Jatkoe; R J Karnes; S J Freedland; Y Wang; A Le; J Baden
Journal:  Br J Cancer       Date:  2015-02-19       Impact factor: 7.640

Review 6.  Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia.

Authors:  Yasuhide Kitagawa; Mikio Namiki
Journal:  Asian J Androl       Date:  2015 May-Jun       Impact factor: 3.285

Review 7.  Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?

Authors:  Ben G L Vanneste; Evert J Van Limbergen; Emile N van Lin; Joep G H van Roermund; Philippe Lambin
Journal:  Biomed Res Int       Date:  2016-12-28       Impact factor: 3.411

8.  Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer.

Authors:  Michael S Leapman; Zhen J Wang; Spencer C Behr; John Kurhanewicz; Ronald J Zagoria; Peter R Carroll; Antonio C Westphalen
Journal:  Radiol Bras       Date:  2017 Sep-Oct

9.  Racial and Ethnic Variation in Health-Related Quality of Life Scores Prior to Prostate Cancer Treatment.

Authors:  Stephanie R Reading; Kimberly R Porter; Jeffrey M Slezak; Teresa N Harrison; Joy S Gelfond; Gary W Chien; Steven J Jacobsen
Journal:  Sex Med       Date:  2017-08-18       Impact factor: 2.491

10.  Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan.

Authors:  Yasuhide Kitagawa; Kazuaki Machioka; Hiroshi Yaegashi; Kazufumi Nakashima; Mitsuo Ofude; Kouji Izumi; Satoru Ueno; Yoshifumi Kadono; Hiroyuki Konaka; Atsushi Mizokami; Mikio Namiki
Journal:  Asian J Androl       Date:  2014 Nov-Dec       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.